Clinical Trial Update: Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Tinengotinib (TT-00420) versus chemotherapy in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 alterations. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Tinengotinib (tinengotinib)

Snippet

Sponsor: TransThera Sciences (Nanjing), Inc. | Conditions: Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING